SB-913

BIOLOGICAL2 trials

Sponsors

Sangamo Therapeutics

Conditions

Hemophilia BMPS IIMucopolysaccharidosis IMucopolysaccharidosis II

Phase 1

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

TerminatedNCT03041324

Sangamo TherapeuticsMPS II, Mucopolysaccharidosis II

Start: 2017-05-11End: 2021-05-07Updated: 2022-10-25

Unknown Phase

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

TerminatedNCT04628871

Sangamo TherapeuticsHemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II

Start: 2020-11-03End: 2026-06-17Updated: 2026-08-13

Related Papers

CRISPR/Cas9: A Potential Life-Saving Tool. What’s next?

Molecular Therapy — Nucleic Acids2017-12-0111 citations